Pegreligrast Inj 6mg Pegfilgrastim

About Pegreligrast Inj 6mg Pegfilgrastim

Pegreligrast 6mg Injection contains Pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor (G-CSF). It is primarily used to stimulate the production of neutrophils, a type of white blood cell that plays a key role in fighting infections. Pegfilgrastim is especially beneficial for patients who experience neutropenia (low white blood cell count) due to chemotherapy.

Key Uses:

1. Chemotherapy-Induced Neutropenia: Pegfilgrastim is used to prevent neutropenia in cancer patients undergoing chemotherapy. Chemotherapy often leads to a decrease in white blood cells, making the body more vulnerable to infections. Pegreligrast 6mg helps increase neutrophil counts, reducing the risk of infections.
2. Bone Marrow Disorders: It can be used in patients with certain conditions that cause low white blood cell counts or following bone marrow transplantation.

Mechanism of Action:

Pegfilgrastim is a modified version of the natural granulocyte colony-stimulating factor (G-CSF). It works by binding to receptors on bone marrow cells, stimulating the production of neutrophils and enhancing the immune system's ability to fight infections.

Common Side Effects:

• Bone pain: This is the most frequent side effect, as the bodys bone marrow increases its production of white blood cells.
• Fatigue or general weakness.
• Headache.
• Injection site reactions: Pain, redness, or swelling at the injection site.

Serious Side Effects:

• Splenic rupture: A rare but serious side effect where the spleen may become enlarged and rupture, causing left abdominal or shoulder pain.
• Acute respiratory distress syndrome (ARDS): Rare, but severe lung complications.
• Severe allergic reactions: Symptoms can include rash, swelling, difficulty breathing, and dizziness.

Dosage:

The usual dose of Pegreligrast 6mg is 6 mg, given once per chemotherapy cycle. The injection is typically administered subcutaneously (under the skin) at least 24 hours after chemotherapy. The injection is usually given in the thigh or abdomen.

Precautions:

• Bone pain: Pain relief may be required to manage bone pain associated with the increased production of white blood cells.
• Pregnancy and breastfeeding: The use of Pegfilgrastim during pregnancy or breastfeeding should be avoided unless absolutely necessary, and only under the supervision of a healthcare provider.
• Monitoring: Regular monitoring of blood counts is necessary to track the effectiveness of treatment and ensure safety.

Summary:

Pegreligrast 6mg Injection is a key treatment for preventing neutropenia in cancer patients undergoing chemotherapy, helping reduce the risk of infections. The injection works by stimulating the production of neutrophils in the bone marrow. While it is generally well-tolerated, it may cause side effects like bone pain and injection site reactions. Serious risks include splenic rupture and allergic reactions, requiring careful monitoring throughout the treatment.

Efficient Neutropenia Management

Pegreligrast provides targeted support for chemotherapy patients, significantly reducing episodes and duration of neutropenia. This helps lower infection risk, safeguarding the patient's overall health during intensive cancer treatment. Its pegylated design guarantees extended action with just one dose per chemotherapy cycle.


User-Friendly Administration

Delivered as a prefilled, portable syringe, Pegreligrast offers single-use convenience and standardized doses with each injection. Healthcare professionals can administer this subcutaneous injection with ease, optimizing workflow in oncology clinics while maintaining patient comfort.


Innovative Technology and Quality Assurance

Pegreligrast is produced via advanced recombinant DNA technology, ensuring high purity and efficacy. Stringent manufacturing processes and rigorous quality controls uphold its standardized dose and sterile composition, giving healthcare providers and patients peace of mind.